MarketCap
Facebook
X
Telegram
Avid Bioservices Income Statement 2024-2009 | CDMO
Brief overview of financial results at Avid Bioservices
The comparison covers a five-year financial horizon. The revenue attributed to Avid Bioservices moved from 53.6 million dollars to 140 million dollars between the two endpoints. Across the full period, sales moved by +161%; the average annual rate was 21.2%. This pace points to rapid expansion of the business.
The gross result shifted from 3.4 million dollars to 7.3 million dollars, or +117.8%. The relationship between sales and direct costs deteriorated. The gross margin was 6.3% at the start and 5.2% at the end. Gross profitability remained broadly stable.
EBITDA was −2.9 million dollars at the beginning and −7.6 million dollars at the end of the period (−163.2%). Changes in revenue did not translate into comparable EBITDA performance. EBITDA margin was −5.4% at the start and −5.4% at the end. Operating profitability remained broadly stable.
Comparing the endpoints shows a move from −$430 thousand to −$141 million. The loss widened and increased the financial risk.
The five-year change in capitalization reached −1.4%: from $429 million to $423 million. The financial trend was stronger than the market valuation.
Overall conclusion
The results contain several connected negative signals. The positive side is supported by consistent operating efficiency and sales growth. The overall view is constrained by a narrow EBITDA buffer, pressure from direct costs and lower net income. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Avid Bioservices
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
423 M | 958 M | 946 M | 1.7 B | 650 M | 429 M | 193 M | 109 M | 57.2 M | 161 M | 1.19 B | 883 M | 582 M | 331 M | - | - |
Shares |
63.2 M | 62.3 M | 61.5 M | 58.2 M | 56.3 M | 56 M | 47.1 M | 37.1 M | 35 M | 26.1 M | 162 M | 120 M | 83.6 M | 60.9 M | 49.1 M | - |
Historical Prices |
6.7 | 15.4 | 15.4 | 29.2 | 11.5 | 7.67 | 4.1 | 2.93 | 1.64 | 6.18 | 7.34 | 7.34 | 6.97 | 5.44 | - | - |
Net Income |
-141 M | 259 K | 128 M | 11.2 M | -10.5 M | -430 K | -1.45 M | -12.6 M | -4.06 M | -13.2 M | -12.1 M | -7.79 M | -8.75 M | -12.1 M | -14.5 M | - |
Revenue |
140 M | 149 M | 120 M | 95.9 M | 59.7 M | 53.6 M | 53.6 M | 57.6 M | 44.4 M | 9.52 M | 6.3 M | 7.35 M | 6.14 M | 4.24 M | 27.9 M | - |
Cost of Revenue |
133 M | 118 M | 82.9 M | 66.6 M | 55.8 M | 46.4 M | 56.5 M | 38.3 M | 23 M | - | - | - | - | - | - | - |
Gross Profit |
7.32 M | 31.5 M | 36.6 M | 29.3 M | 3.93 M | 3.36 M | 334 K | -3.46 M | 7.93 M | 4.78 M | 2.12 M | 3.16 M | 2.36 M | 436 K | - | - |
Operating Income |
-18.7 M | 3.6 M | 15.4 M | 12.2 M | -10.9 M | -5.62 M | -20.6 M | 1.29 M | 3.49 M | -50.5 M | -35.7 M | -28.4 M | -42.1 M | -34.7 M | -13.6 M | - |
Interest Expense |
4.34 M | 3.01 M | 2.68 M | 1.16 M | 8 K | 11 K | - | - | - | 1 K | 5 K | 54 K | 90 K | 516 K | 997 K | - |
EBITDA |
-7.57 M | 10.8 M | 19.9 M | 15.7 M | -7.85 M | -2.88 M | -18.1 M | 3.76 M | 5.02 M | -49.5 M | -34.7 M | -27.3 M | -41.2 M | -34 M | -13.2 M | - |
Operating Expenses |
26 M | 27.9 M | 21.2 M | 5.06 M | 4.17 M | 3.89 M | 16.5 M | 47.6 M | 78.1 M | 61.7 M | 45 M | 37.4 M | 47.2 M | 40.9 M | - | - |
General and Administrative Expenses |
26 M | 27.9 M | 21.2 M | 17.1 M | 14.5 M | 12.8 M | 16.5 M | 18.1 M | 17.9 M | 18.7 M | 17.3 M | 13.1 M | 11.5 M | 11.4 M | 8.18 M | - |
All numbers in USD currency
Quarterly Income Statement Avid Bioservices
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
63.8 M | 63.6 M | 63.3 M | 63.1 M | 62.8 M | 63.3 M | 62.4 M | 62.8 M | 61.9 M | 62.4 M | 61.6 M | 62.2 M | 61.8 M | 58.9 M | 58.9 M | 56.7 M | 61.1 M | 56.4 M | 56.4 M | 56.3 M | 56.2 M | 56.1 M | 56.1 M | 56 M | 55.8 M | 45.2 M | 45.2 M | 45.1 M | 44.8 M | 37.3 M | 261 M | 245 M | 240 M | 227 M | 227 M | 204 M | 197 M | 183 M | 183 M | 180 M | 179 M | 163 M | 163 M | 157 M | 149 M | 131 M | 131 M | 109 M | 103 M | 87.1 M | 87.1 M | 77.5 M | 71.7 M | 64.4 M | 77.5 M | 74.1 M | 69.8 M |
Net Income |
-17.4 M | -5.53 M | -6.01 M | -9.52 M | -2.12 M | -6.01 M | 461 K | -2.12 M | 1.56 M | -247 K | 2.25 M | -1.16 M | - | 2.21 M | 2.21 M | 2.28 M | 6.3 M | -2.1 M | -2.1 M | -430 K | -3.16 M | -1.14 M | -1.14 M | -1.45 M | -1.96 M | -11 M | -11 M | -12.6 M | -1.2 M | -7.77 M | -7.77 M | -4.06 M | -11.1 M | -16.8 M | -16.8 M | -13.2 M | -13.7 M | -13 M | -13 M | -12.1 M | -13.1 M | -9.72 M | -9.72 M | -7.79 M | -7.6 M | -4.91 M | -4.91 M | -8.75 M | -7.66 M | -11.1 M | -11.1 M | -12.1 M | -8.09 M | -8.93 M | -12.1 M | -12.1 M | -8.09 M |
Revenue |
33.5 M | 40.2 M | 33.8 M | 25.4 M | 37.7 M | 33.8 M | 38 M | 37.7 M | 36.7 M | 38 M | 31.5 M | 34.8 M | 61.8 M | 31.5 M | 21.8 M | 21.1 M | 30.8 M | 13.6 M | 13.6 M | 18.3 M | 15.3 M | 13.8 M | 13.8 M | 10.2 M | 12.6 M | 6.82 M | 10.2 M | 10.2 M | 12.6 M | 10.7 M | 10.7 M | 23.4 M | 5.61 M | 6.71 M | 6.71 M | 9.52 M | 9.67 M | 5.68 M | 5.68 M | 6.3 M | 5.5 M | 3.88 M | 3.88 M | 7.35 M | 4.69 M | 7.04 M | 7.04 M | 6.14 M | 4.25 M | 3.28 M | 3.28 M | 4.23 M | 5.66 M | 2.88 M | 4.24 M | 4.23 M | 5.66 M |
Cost of Revenue |
35.5 M | 34.5 M | 31.4 M | 30.1 M | 33.6 M | 31.4 M | 28.2 M | 33.6 M | 27.6 M | 28.2 M | 22.4 M | 30.6 M | - | 15.6 M | 15.6 M | 14.6 M | 19.4 M | 12.8 M | 12.8 M | 15 M | 14.2 M | 11.7 M | 11.7 M | 9.84 M | 11.4 M | 11 M | 9.84 M | 9.84 M | 11.4 M | - | 16.2 M | 20.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
-2.04 M | 5.71 M | 2.38 M | -4.66 M | 4.1 M | 2.38 M | 9.82 M | 4.1 M | 9.12 M | 9.82 M | 9.09 M | 4.15 M | - | 6.2 M | 6.2 M | 6.42 M | 11.4 M | 785 K | 785 K | 3.36 M | 1.09 M | 2.05 M | 2.05 M | 334 K | 1.19 M | -4.13 M | -4.13 M | -3.46 M | 6.63 M | 2.77 M | 2.77 M | 7.93 M | 2.55 M | 2.78 M | 2.78 M | 4.78 M | 4.77 M | 2.56 M | 2.56 M | 2.12 M | 1.91 M | 1.47 M | 1.47 M | 3.16 M | 1.91 M | 3.31 M | 3.31 M | 2.36 M | 2.11 M | 719 K | 2.36 M | 2.36 M | 2.11 M | - | 436 K | 2.42 M | - |
Operating Income |
-12.6 M | -2.46 M | -4 M | -11.2 M | -2.16 M | -4 M | 2.72 M | -2.16 M | 2.74 M | 2.72 M | 3.27 M | -2.68 M | - | 2.18 M | 2.18 M | 2.25 M | 6.93 M | -2.21 M | -2.21 M | -529 K | -3.37 M | -1.19 M | -1.19 M | -2.48 M | -2.02 M | -8.96 M | -8.96 M | -12.6 M | -1.23 M | -1.59 M | -7.8 M | -4.08 M | -11.1 M | -16.9 M | -16.9 M | -13.8 M | -13.8 M | -13 M | -13 M | -12.1 M | -13.2 M | -9.74 M | -9.74 M | -7.81 M | -7.62 M | -5.16 M | -5.16 M | -7.06 M | -7.67 M | -11.1 M | -11.1 M | -12 M | -8.05 M | -8.84 M | -12 M | -12 M | -8.05 M |
Interest Expense |
3.28 M | 2.45 M | 875 K | 827 K | 825 K | 875 K | 620 K | 825 K | 518 K | 636 K | 718 K | 703 K | - | - | 704 K | 1.41 M | 703 K | - | - | 4 K | - | - | - | - | - | - | - | - | - | 2 K | 2 K | - | - | 14 K | 20 K | - | - | 1 K | 1 K | - | - | 4 K | 4 K | - | 1 K | 8 K | 8 K | 44 K | 1 K | 6 K | 6 K | 28 K | 54 K | 106 K | 28 K | 28 K | 54 K |
EBITDA |
-5.84 M | 368 K | 4.25 M | -5.79 M | 486 K | -1.2 M | 8.04 M | 486 K | 4.32 M | 4.62 M | 6.33 M | 725 K | - | 3.08 M | 4.72 M | 3.94 M | 7.94 M | -1.41 M | -1.41 M | 171 K | -2.65 M | -492 K | -511 K | -1.8 M | -1.38 M | -8.31 M | -8.31 M | -12 M | -587 K | -961 K | -7.17 M | -3.47 M | -10.5 M | -16.4 M | -16.4 M | -13.6 M | -13.5 M | -12.8 M | -12.8 M | -11.9 M | -12.9 M | -9.5 M | -9.5 M | -7.58 M | -7.36 M | -4.88 M | -4.88 M | -6.79 M | -7.41 M | -10.9 M | -10.4 M | -11.6 M | -7.85 M | -8.84 M | -11.8 M | -11.8 M | -8.05 M |
Operating Expenses |
10.6 M | 8.17 M | 6.38 M | 6.56 M | 6.26 M | 6.38 M | 7.11 M | 6.26 M | 6.38 M | 7.11 M | 5.82 M | 6.83 M | - | 4.02 M | 4.02 M | 4.17 M | 5.06 M | 3 M | 3 M | 3.89 M | 3.53 M | 3.24 M | 3.24 M | 2.82 M | - | 4.82 M | 2.82 M | 2.82 M | - | - | 4.85 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
10.6 M | 8.17 M | 6.38 M | 6.56 M | 6.26 M | 6.38 M | 7.11 M | 6.26 M | 6.38 M | 7.11 M | 5.82 M | 6.83 M | - | 4.02 M | 4.02 M | 4.17 M | 4.46 M | 3 M | 3 M | 3.53 M | 4.46 M | 3.24 M | 3.24 M | 2.82 M | 3.22 M | 4.82 M | 4.82 M | 3.87 M | 4.21 M | 4.36 M | 4.58 M | 4.98 M | 5.06 M | 4.52 M | 4.52 M | 4.42 M | 4.9 M | 4.32 M | 4.32 M | 4.3 M | 4.88 M | 4.56 M | 4.56 M | 4.02 M | 4.33 M | 3.11 M | 3.11 M | 3.44 M | 2.92 M | 2.71 M | 2.71 M | 2.73 M | 2.93 M | 2.95 M | 2.73 M | 2.73 M | 2.93 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Avid Bioservices (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Belgium
Cayman-islands
